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A wide range of regulatory standards applicable to production and use of tissues, cells, and other
biologics (or biologicals), as advanced therapies, indicates considerable interest in the regulation of
these products. The objective of this study was to analyze and compare high-tier documents within
the Australian, European, and U.S. biologic drug regulatory environments using qualitativemethod-
ology. Eighteen high-tier documents from the European Medicines Agency (EMA), U.S. Food and
Drug Administration (FDA), and Therapeutic Goods Administration (TGA) regulatory frameworks
were subject to automated text analysis. Selected documents were consistent with the legal re-
quirements for manufacturing and use of biologic drugs in humans and fall into six different cate-
gories. Concepts, themes, and their co-occurrencewere identified and compared. Themost frequent
concepts in TGA, FDA, and EMA frameworks were “biological,” “product,” and “medicinal,” respec-
tively. This was consistent with the previousmanual terminology search. GoodManufacturing Prac-
tice documents, across frameworks, identified “quality” and “appropriate” as main concepts,
whereas in Good Clinical Practice (GCP) documents it was “clinical,” followed by “trial,” “subjects,”
“sponsor,” and “data.” GCP documents displayed considerably higher concordance between differ-
ent regulatory frameworks, as demonstrated by a smaller number of concepts, similar size, and
similar distance between them. Although high-tier documents often use different terminology, they
share concepts and themes. This paper may be a modest contribution to the recognition of similar-
ities and differences between analyzed regulatory documents. It may also fill the literature gap and
provide some foundation for future comparative research of biologic drug regulations on a global
level. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:909–920
INTRODUCTION
Although therapeutics derived from biological
sources have been subject to regulatory over-
sight for some time (i.e.,monoclonal antibodies),
the biologic products used in transplantation
procedures (i.e., cells and tissues) have histori-
cally been exempted from such oversight [1]. The
unique source of the “active ingredients” ren-
ders biologic drugs difficult to assess by tradi-
tional regulatory systems,which provide support
to conventional pharmaceutical manufacturing
processes [2]. New considerations have led the
existing regulatory agencies of the developed
world to propound new regulatory approaches
for the sector of biologic drugs or biopharmaceu-
ticals that “has become one of the most re-
search-intensive sectors with a great potential
for delivering innovative humanmedicines in the
future” [3]. Regulation of cell and tissue products
is closely linked not only to sensitive areas of
public health policy and funding but also to the
development of novel disciplines such as regula-
tory science [4, 5]. Biologic drug regulations are
widely developed by mature regulatory agen-
cies; for example, the Australian framework is
administered by the Therapeutic Goods Admin-
istration (TGA), the European Union’s by the Eu-
ropeanMedicines Agency (EMA), and that of the
U.S. by the Food and Drug Administration
(FDA) [6].
The intention of this research is to compare
the content and terminology in high-tier regula-
tory documents related to biologic drugs in
Australia [7–10], Europe [11, 12], and the U.S.
[13–16], where these products are also referred
to as biologicals, advanced therapy medicinal
products, and biologics, respectively. It was hy-
pothesized that there are similarities between
them although the terminology and focus of
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regulatory frameworks differ to some extent. It was also antici-
pated that high-tier regulatory documents could be taken as a
central representation of the regulatory frameworks fromwhich
they were drawn. The overall aim of the study was to establish a
correlation betweenmanual [17] and software-based documen-
tary analysis, to assess usability of the software analysis, and to
ascertain the use of a qualitative methodology in the highly spe-
cialized area of regulatory science. Additionally, the aim of this
approach was to contribute to a generalization rather than a
simple statement of sameness or difference between the docu-
ments, not only for the sake of future development of biologic
drugs but for further development of associated regulations in
less developed regional and national regulatory sets of principles
(i.e., Southeast Asian or Eastern European countries).
An inherent complexity, the historical background, and the
differences between regulatory frameworks applicable to bio-
logic drug development and application are reflected in the ter-
minology they use [17]. The computer-aided qualitative data
analysis (CAQDAS) software [18] Leximancer v3.1 (Leximancer
Pty. Ltd., Jindalee, QLD, Australia, https://www.leximancer.
com), was used in this research [19]. The documents required
the ability to analyze them while applying other skills, such as
recognizing certain textual forms or genres, and the ability to
judge, interpret, or contextualize [20, 21]. Concepts and themes
were identified (conceptual analysis) in groups of documents,
and the co-occurrence patterns between them (relational anal-
ysis) were explored across the entire data corpus [22]. It is antic-
ipated that during the future harmonization of regulations and
guidances these similarities can potentially be used as a feasible
source of knowledge and expertise.
Theory of Terminology
The general theory of terminology arises from the work of
Wu¨ster (1898–1977), and it is based on the significance of con-
cepts and their delineation from each other [23]. The nature of
concepts, conceptual relations, relationships between terms and
concepts, and the designation of terms from concepts are the
main features of the general theory of terminology [24]. The
domain of concepts is seen as independent from the domain of
terms, and terminology delineation continuously flows from
concepts working their way to terms [25]. Although the general
theory of terminology has been criticizedbyother authors—such
as its naivety in presenting the concept as a cornerstone of any
terminology [26] or being overly reliant upon semantics [27]—it
provides a relevant start point for this research [23]. First, it
enhances the features of the software used in documentary
analysis. Second, the descriptive structure of concepts in this
theory (i.e., assigning a bundle of characteristics to a concept)
fulfills the need of the research to compare but not analyze spe-
cific characteristics. Finally, terminology or specialized language
is more than a technical or particular instance of general lan-
guage in the modern society in which we live [25]. In today’s
society with its emphasis on science and technology, the way
specialized concepts are named, structured, described, and un-
derstood has put terminology in the spotlight. The information in
scientific and technical texts is encoded in terms or specialized
knowledge units, which can be regarded as access points tomore
complex knowledge structures. As such, they onlymark the tip of
the iceberg [25]. Complex knowledge beneath the surface can be
considered a concept or a collection of specialized knowledge
[25]. The specialist knowledge may be inherent to a scientific
discipline represented by an entity or a group of experts (i.e., a
regulatory agency). This specialized knowledge may be repre-
sented, along with its specific characteristics, within the publica-
tions (i.e., scientific journals) or documents (i.e., high-tier regu-
latory documents). Hence, the general terminology theory’s
attitude toward a concept makes a valid approach for this par-
ticular analysis. It is important to state that any attempt toward
semantic analysis, analysis of the rules of syntax, or cognitive
aspects of the language and terminology are beyond the scopeof
this study.
Sampling Considerations
Most intellectual work involved in sampling and selection con-
cerns establishing an appropriate relationship between the sam-
ple and the wider universe. There were both empirical and the-
oretical elements to this study. In an empirical sense this
research involved the groups, countries/regions, policies, con-
siderations, and a broad spectrum of activities related to cell and
tissue therapies or biologic drug development, manufacturing,
and application. In a theoretical sense this research entailed
some of the theories emerging from the social sciences and ap-
plied them to the complex world of regulatory science. While
doing so, the study conveys complexity on numerous levels re-
lating to regional regulations (in terms of the scope, biologic drug
groups, and related terminology) [28] and complexity of the re-
searchmethodology [17]. The samplingwas not inherently about
empirical representation, as it tends to be in some quantitative
forms of research [21]. The type of sampling used in this research
was theoretical or purposive sampling for high-tier regulatory
documents that are, for the purposes of this research, taken as a
central representation of the regulatory frameworks fromwhich
they were drawn.
Software Considerations
Content analysis is a research tool used for determining the pres-
ence of words or concepts in collections of textual documents
[29]. It is used for breaking down the material into manageable
categories and relations that can be quantified and analyzed.
These extracted measurements can be used to make valid infer-
ences about the material contained within the text [29]. Lexi-
mancer software is increasingly used instead of hand coding, and
it has advantages in some research domains [30]. It has been
used in research to analyze opinion polls [31], to assess enter-
prise risks in a specific industry [32, 33], to evaluate marine op-
erations accidents [34] and academic performance characteris-
tics [35], and to track changes in journals [36]. It has also been
applied in health research into practitioner training and percep-
tions of common practices [37, 38], patient safety and incident
reports [39], patient management and perceptions of health
care [40], and assessing the change of health practices [41].
As in this study, Leximancer has been applied to concept
mapping in different contexts [42, 43] and for the purpose of
identifying themes and patterns [44, 45]. Although it has been
applied extensively, the use of Leximancer software in this study
was somewhat unusual. To our knowledge, this the first study to
apply Leximancer software to assess high-tier, or any other, reg-
ulatory documents pertinent to biopharmaceuticals, biologics,
or any other medicinal products.
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MATERIALS AND METHODS
Materials
The study design, including document selection criteria and quali-
tative research considerations, has been already explained in detail
[17].Anextensive list of selecteddocuments is presented inTable1.
Methods
The CAQDAS software [18] Leximancer v3.1 was used to identify
concepts and themes across a range of documents and provide
correlation analysis to some extent [19]. Using documents or
texts as a source of data required the ability to analyze themwhile
applying other skills, such as recognizing certain textual forms or
genres, and the ability to judge, interpret, or contextualize [20, 21].
In the process of moving the documents from converting sets of
data into meaningful findings it was important to decide the intent
for deriving and presenting data. The process involved obtaining
documents fromtheofficialwebsites [7–16]andanalyzing themina
comparative manner using the software. Concepts and themes
were identified (conceptual analysis) in groups of documents, and
the co-occurrence patterns between them (relational analysis)
were explored across the entire data corpus.
RESULTS
Documents presented in Table 1 (cohorts 1 and 2) were analyzed
by Leximancer v3.1 software content analysis, and the data are
presented in Tables 2–4 and Figures 1–4. After processing
groups of documents, a range of datawas generated—concepts,
Table 1. List of analyzed documents










EMA DOC1 Directive 2001/83/EC n/a 2001 Yesa
EMA DOC2 Regulation 726/2004 n/a 2004 Yesa
EMA DOC3 Regulation 1394/2007 n/a 2007 Yes
FDAb
Document Code
FDA DOC1 21CFR312 n/a 2011 Yes
FDA DOC2 21CFR600 Biological Products: General n/a 2011 Yes





TGA DOC1 Australian Regulatory Guidelines for Biologicals Part 1 1.0 2011 Yes
TGA DOC2 Australian Regulatory Guidelines for Biologicals Part 2 1.0 2011 Yes
TGA DOC3 Australian Regulatory Guidelines for Biologicals Part 3 1.0 2011 Yes
Cohort 2
Good Manufacturing Practice (1)
Document Code
GMP DOC1 Directive 2003/94/EC (EMA) n/a 2003 Yes
GMP DOC2 Australian Code of Good Manufacturing Practice—Human Blood
and Tissues (TGA)
n/a 2000 Yesc
GMP DOC3 Australian Code of Good Manufacturing Practice for Medicinal
Products (TGA)
n/a 2002 Yes
Good Manufacturing Practice (2)
Document Code
GMP DOC4 21CFR211 Current Good Manufacturing Practice for Finished
Pharmaceuticals (FDA)
n/a 2011 Yes
GMP DOC5 Guide to Good Manufacturing Practice for Medicinal Products—
Part I (PIC/S)
n/a 2009 Yes





GCP DOC1 Directive 2003/20/EC (EMA) n/a 2001 Yes
GCP DOC2 Guidance for Industry E6 Good Clinical Practice (FDA) n/a 1996d Yes




bDisclaimer: Major, specific, and updated FDA guidances relating to key subsets of biologics were not included in cohort 1 and 2 documents.
Although the basic FDA regulations have not been changed much since the expansion of biologic drugs, including vaccines, the guidances have
really become more like regulations in the interim. Due to the research sampling criteria, guidances (including the key manufacturing guidances for
biologics that the FDA really does enforce in a way similar to that for regulations) have not been analyzed here. These documents can be found at
the following link: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.
cIn the process of being amended.
dDocument was exempt from the time frame.
Abbreviations: DOC, document; API, Active Pharmaceutical Ingredients; CFR, Code of Federal Regulations; EMA, European Medicines Agency; FDA,
Food and Drug Administration; GCP, Good Clinical Practice; GMP, Good Manufacturing Practice; n/a, not applicable; PIC/S, Pharmaceutical
Inspection Convention/Cooperation Scheme; TGA, Therapeutic Goods Administration.
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concept clouds, concept maps, themes, and thematic
summaries. The data presented in the study appear in the form
of the following figures and tables:
● Primary concept maps (Fig. 1) and concept clouds (Fig. 2)
● Centrality of each concept (Figs. 2 and 4)
● Concept co-occurrence (Fig. 3)
● Central themes (Fig. 4)
● Document summary (supplemental online data 1)
● Thematic summary (supplemental online data 2)
● Main concepts discussed in the document set (Table 2)
Table 2. Frequently occurring concepts in the software documentary analysis (cohorts 1 and 2)
Concepts in order of frequency 1 2 3 4 5
Documents in individual regulatory frameworks
TGA Biological Human Section Trial
FDA Product Section Used HCT CFR
EMA Medicinal Marketing Commission Directive Public
Documents across regulatory frameworks
GMP (1) Quality Materials Product Contamination Manufacture
GMP (2) Appropriate Drug Records API
GCP Clinical Trial Subjects Sponsor Data
Abbreviations: API, Active Pharmaceutical Ingredients; CFR, Code of Federal Regulations; EMA, European Medicines Agency; FDA, Food and Drug
Administration; GCP, Good Clinical Practice; GMP, Good Manufacturing Practice; HCT, human cell and tissues; TGA, Therapeutic Goods
Administration.
Table 3. Thematic summary in individual regulatory frameworks and across regulatory areas (cohorts 1 and 2)














Biological 100 Section 100 Medicinal 100 Quality 100 Appropriate 100 Sponsor 100
Class 46 Donor 82 Marketing 88 Product 91 Drug 50 Subjects 66
Use 44 Product 53 Referred 59 Materials 73 Use 45 Trial 56
Biologicals 42 HCT 49 Community 29 Products 63 Batch 40 Written 34
ARTG 34 Including 46 Directive 28 Used 46 Used 39 Clinical 28
Human 20 Manufacture 39 Market 15 Manufacture 36 Manufacture 28 Products 18
Medical 15 Products 21 Agency 12 Validation 26 Written 25 Product 15
Section 10 Requirements 19 Appropriate 10 System 26 Established 23 Adverse 03
Trial 02 FDA 11 Human 10 Contamination 19 API 22
Page 01 Drug 05 Therapy 09 Area 18 Maintained 09
Commission 09 Containers 08 Apis 08
Filling 06 Personnel 04
Manufacture 03 Data 03
In the full software interface, a list of concepts ranked by their frequency is displayed below the map.
aConnectivity is a measure of co-occurrence between the concepts and the degree of association between them.
Abbreviations: API, Active Pharmaceutical Ingredients; ARTG, Australian Register of Therapeutic Goods; FDA, Food and Drug Administration; HCT;
human cell and tissues.
Table 4. Frequency and connectivity of themes identified in individual regulatory frameworks and across regulatory areas (cohorts 1 and 2)



















91 100 Biological Section Medicinal Quality Appropriate Sponsor High (9/65)
Product
81 90 Donor Marketing
51 80 Product Referred Materials Subjects Medium (41/65)
Products Trial
11 50 Class HCT Community Used Drug Written
Use Including Directive Manufacture Use Clinical
Biologicals Manufacture Market Validation Batch Products
ARTG Products Agency System Used Product
Human Requirements Contamination Manufacture Adverse
Medical FDA Area Written
Established
API
10 Section Drug Appropriate Containers Maintained Low (15/65)
Trial Human Filling Apis
Page Therapy Manufacture Personnel
Commission Data
In the full software interface, a list of concepts ranked by their frequency is displayed below the map.
aConnectivity is a measure of co-occurrence between the concepts and the degree of association between them.
Abbreviations: API, Active Pharmaceutical Ingredients; ARTG, Australian Register of Therapeutic Goods; EMA, European Medicines Agency; FDA,
Food and Drug Administration; GCP, Good Clinical Practice; GMP, Good Manufacturing Practice; HCT, human cell and tissues; TGA, Therapeutic
Goods Administration.
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● Similarity in contexts in which the concepts occur such as thematic
groups (themes) and relative frequencies of the concepts (Table 3)
● Connectivity of themes (Table 4)
The concept maps appeared different with regard to their
complexity, number of concepts, or size of the circles around
them. Each map displayed important sources of information
about the analyzed text, as demonstrated in Figures 1A–1F. Al-
thoughdifficult to read (because of the number of concepts iden-
tified by the software), the TGA concept map is presented in
Figure 1C. It is an example of a set of documents discussing nu-
merous topics, which are represented by the vastness of over-
lapping concepts.
The first Good Manufacturing Practice (GMP) concept cloud
(Fig. 2A) appeared wider and busier, with the spread of numer-
ous concepts surrounding the centrally positioned “product.” It
encompassed analysis of diverse GMP documents from the EMA
and the TGA regulatory frameworks, which is reflected in a di-
verse and broad range of concepts. The second GMP concept
cloud (Fig. 2B) revolves around the central concept “appropri-
ate” closely encircled with “procedures,” “processing,” “qual-
ity,” and “control.” Its wide circle reaches to “intended” and
“use” on one side and “batch” and “records” on the other side.
Overall, the second GMP concept cloud (Fig. 2B) appeared rela-
tively narrow compared with the first GMP concept cloud (Fig.
2A). It covered analysis of two medicinal product GMP docu-
ments and the GMP code of the finished pharmaceutical prod-
ucts reflecting its coherence. The Good Clinical Practice (GCP)
concept cloud (Figure 2C) was the most consistent, with a fairly
narrow range of concepts surrounding “sponsor” and “trial” oc-
cupying the central positions. This clearly reflects the focus of all
GCP documents revolving around one central concept. On the
contrary, the EMAconcept cloud (Fig. 2D) and TGA concept cloud
(Fig. 2E) revolved around their vertical and horizontal axes, re-
spectively, thus reflecting the diversity and wider spread of the
concepts.
The concept clouds in Figure 2 are a useful illustration of
differences between the documents’ content. For instance, the
content of the documents in the EMA (Fig. 2D) and the TGA can
be compared visually (Fig. 2E). The EMA concept cloud appears
rather focused (‘narrower” than the TGA cloud) with the cen-
tral or primary concepts “medicinal” and “products” and with
a number of secondary concepts, such as “marketing,” “au-
thorization,” “holder,” and “referred” (Fig. 2D). The TGA con-
cept cloud features the central concepts “biological” and
“class,” with a wider spread of other concepts around them.
These include “human” and “products” on one side and “in-
formation” and “application” on the other side of the TGA
concept cloud (Fig. 2E). A similar observation is applicable in
the comparison of GMP and GCP documents across different
regulatory frameworks.
Different colors indicated different thematic groups
(themes) surrounded by circles. They form around highly con-
nected concepts, which are parents of thematic clusters [19, 22].
Figure 1. Concept maps. (A–C): Concepts identified in individual regulatory frameworks’ documents: European Medicines Agency docu-
ments (A), FDA documents (B), and TGA documents (C). (D–F): Concepts identified in documents across regulatory frameworks: Good
Manufacturing Practice (GMP) (1) documents (D), GMP (2) documents (E), and Good Clinical Practice documents (F). For a list of the specific
documents in each group, see Table 1. Abbreviations: API, Active Pharmaceutical Ingredients; CFR, Codeof Federal Regulations; FDA, Food and
Drug Administration; FR, Federal Regulations; TGA, Therapeutic Goods Administration.
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Figure 2. Concept clouds and themes. (A–C): Concept clouds identified by the software in documents across regulatory frameworks: Good
Manufacturing Practice (GMP) (1) documents (A), GMP (2) documents (B), and Good Clinical Practice (GCP) documents (C). (D–F): Concept
clouds identified in individual regulatory frameworks’ documents (D, E) and overlay of themes (F) identified by the software across regulatory
frameworks in GCP documents: European Medicines Agency documents (D), TGA documents (E), and GCP documents related concepts and
themes (overlay of words is a reflection of the concepts’ closeness) (F). For a list of the specific documents in each group, see Table 1.
Abbreviations: API, Active Pharmaceutical Ingredients; ARTG, Australian Register of Therapeutic Goods; EC, Ethics Committee; IEC, Institu-
tional (Independent) Ethics Committee; IRB, Institutional Review Board; TGA, Therapeutic Goods Administration.
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For example, the map in Figure 2F presents analysis of GCP doc-
uments across different regulatory frameworks with a similar
“separateness” of concepts and their specific connectivity—rep-
resented not only by color but also by the distance between
them. The GCP documents displayed considerably higher con-
cordance between different regulatory frameworks than other
analyzed documents. The central theme “trial” was closely sur-
rounded by the themes “sponsor,” “subjects,” “data,” “clinical,”
“accordance,” and “adverse.” Themes such as “written,” “includ-
ing,” and “days” were reasonably remote but still linked to the
central theme “trial.” The theme “sponsor” consisted of the con-
cepts “sponsor,” “regulatory,” “protocol,” and “opinion,” and
the theme “subjects” contained concepts such as “provided,”
“information,” and “consent” closely linked to the theme “data”
(and the concept “data”). The themes “clinical” and “products”
were also in close proximity—demonstrating their relatedness
Figure 3. Correlation of concepts across data corpus. Pairs of concepts correlation (co-occurrence) identified by the software across the
entire data corpus for the Food and Drug Administration documents (A), Therapeutic Goods Administration documents (B), European
Medicines Agency (C), GoodManufacturing Practice (GMP) (1) (D) and GMP (2) documents (E), and Good Clinical Practice document analysis
(F). Colored slices on the graphpresent relative frequencies of the key co-occurring concepts. For a list of the specific documents in each group,
see Table 1. Abbreviations: API, Active Pharmaceutical Ingredients; FR, Federal Regulations; IEC, Institutional Ethics Committee; TGA, Ther-
apeutic Goods Administration.
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in the documents but slightly more remote from the themes
“sponsor,” “written,” or “data,” as these did not occur near each
other in the documents. The example of the close co-occurrence
and remoteness of the themes is obvious in the following ex-
cerpts from the GCP documents: “(a) the informed consent of
the legal representative has been obtained; consent must
represent the subject’s presumedwill andmay be revoked at any
time, without detriment to the subject; …” (Directive 2003/
20/EC [EMA]) and, “In obtaining and documenting informed con-
sent, the investigator should comply with the applicable regula-
tory requirement(s), and should adhere to GCP and to the ethical
principles that have their origin in the Declaration of Helsinki”
(Guidance for Industry E6 Good Clinical Practice [FDA]).
Furthermore, the software automatically extracted themost
important concepts discussed in the documents being pro-
cessed. In the maps of the analyzed documents, the five most
frequent concepts were very different, as shown in Table 2.
The major themes in the TGA, FDA, and EMA regulatory
frameworks and the same group documents (i.e., GMP and GCP)
across different regulatory frameworks are presented as the-
matic summaries in Table 3. The thematic summaries of analyzed
documents mostly consist of a broad range of themes and their
frequency significantly varies. However, some common ground
was found between them. For example, in two groups of docu-
ments, GMP (1) andGMP (2), 8 of top 12 concepts (66.66%)were
exactly the same (“product(s),” “quality,” “materials,” “control,”
“used,” “equipment,” “procedures,” and “use”), and 2 of 12 con-
cepts (16.66%) were interchangeable (“medicinal”/“drug” and
“manufacturing”/“production”). Hence, 10 of the 12 most fre-
quently co-occurring concepts (83.33%)were shared between all
GMP documents in the analysis, irrespective of the frameworks
from which they originate, whereas only 2 of the most frequent
concepts were entirely different (“appropriate” and “batch”).
Further analysis presented in Table 4 shows connectivity of
themes as a measure of connectedness between them. If all the
themes across regulatory frameworks and regulatory areaswere
grouped according to their connectivity range, a high range
(81%–100%) of connectivity was found in only 9 themes (of 65
themes in total), whereas a majority of themes convened within
a medium connectivity range (11%–80%). Sometimes a theme
with a relatively high frequency was not connected to other
themes, and hence its connectivity range was low (i.e., “drug” in
the FDA regulatory documents).
The co-occurrence between concepts in the text was an im-
portant measure of the degree of association between them.
Hence, the three-dimensional (3D) graphs in Figure 3 are pre-
sented to illustrate the co-occurrence of the concepts and prox-
imity analysis in individual frameworks’ documents (FDA, TGA,
EMA), as well as across the set of documents applicable to GMP
and GCP requirements. Proximity analysis measured the co-oc-
currence of concepts found within the text. In this approach a
window, based on a length of words or sentences, was specified
andmoved sequentially through the text, taking note of the con-
cepts that occurred together. In the EMA documents the co-
occurrence of pairs of concepts was in the maximum frequency
range of 7,000–8,000 (Fig. 3C), whereas the FDA and the TGA
documents had maximum concept co-occurrence of up to 1,000
(Fig. 3A and 3B, respectively). This measure depends not only on
individual frequency of the concepts but also on the co-occur-
rence of the concepts (their connectedness) [19, 22]. For in-
stance, the individual frequency of the concept “medicinal” was
Figure 4. Most frequent themes and concepts. Most frequent
themes and their concepts identified by the software in FDA docu-
ments (overlay of words is a reflection of concepts’ closeness) (A),
EuropeanMedicines Agency documents (B), and Therapeutic Goods
Administration documents (presented here as an example of a
strong contextual similarity) (C). For a list of the specific documents
in each group, see Table 1. Abbreviations: ARTG, Australian Register
of Therapeutic Goods; CFR, Code of Federal Regulations; FDA, Food
and Drug Administration; HCT, human cell and tissues.
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greater than 1,000 in three EMA documents analyzed manually.
Nevertheless, because of their connectedness, the total of their
frequency presented on the co-occurrence graph generated by
the software analysis was in the range of 7,000–8,000 (Fig. 3C).
A group of concepts, which appear in the text close to each
other,was identified as part of the same theme. Themost central
themes (and concepts within those) are presented in Figure 4.
The central themes encompassed “product,” “medicinal,” and
“biological” in FDA, EMA, and TGA frameworks, respectively, and
the central concepts containedwithin the central themes ranged
from “biological,” “licensed,” and “manufacturer” (FDA) to “dos-
sier,” “goods,” and “clinical” (TGA). In some instances, central
themes included the abbreviated name of a regulatory registry
(i.e., “ARTG”), reference to a legal entity (i.e., “Commission”), or
reference to a legal document (i.e., “Directive” or “CFR”). Repre-
sentation of central themes in Figure 4 to some extent reflects
themain focus of regulatory documents scrutinized in this study.
It appeared that the FDA documents revolve around themes
“HCT” (human cell and tissues) or “product” with frequent refer-
ences to “CFR” and “section,”whereas the EMAdocumentswere
mostly dominated by “medicinal” (product), “marketing,” and
“public,” with numerous citations of “Commission” and “Direc-
tive.” Interestingly, the TGA document analysis demonstrated
only two main central themes, “biological” (with numerous con-
cepts) and “human”; its reference is mostly to “section” and
“Australian Regulatory Guidelines for Biologicals” (mentioned as
one of the concepts within the central themes).
The last block of information visible from the map was the
contextual similarity between concepts. The map was con-
structed by initially placing the concepts randomly on the grid.
Each concept exerted a pull on each other concept with a
strength related to their co-occurrence value. Concepts can be
thought of as being connected to each other with springs of
various lengths [19, 22]. The more frequently two concepts co-
occur, the stronger are the forces of attraction that bring fre-
quently co-occurring concepts together [19, 22]. However, be-
cause there are many forces of attraction acting on each
concept, it is impossible to create a map in which every concept
is at the expected distance away from every other concept.
Rather, concepts with similar attractions to all other concepts
will cluster together [19, 22]. If regulatory agencies talk about
similar issues, these issues (or concepts) will appear closer to-
gether than those of different agencieswith different agendas or
different intentions.
An example of contextual similarity was evident in the TGA
documents outlining the Biologicals Framework, where themost
frequent co-occurring themes (and concepts within those
themes) are presented in Figure 4C. Although the concepts “ap-
plication” and “information” do not have a direct link in the text
(they never appear together), they appeared adjacent on the
map due to the similarities of the contexts (i.e., themes) in which
they appear. Furthermore, these words appeared clustered
close together with other significant words, such as “dossier,”
“processing,” and “goods,” that appear in similar contexts in the
documents. A thematic grouping of “blood,” “human,” “cells,”
and “product” (or “products”) was also apparent. An entirely
separate domain on the map presented the “Australian Regula-
tory Guidelines for Biologicals” and “section” drawn together by
the similarities of the contexts in which they appear (but distant
from the other concepts on the map).
In addition to a document summary in supplemental online
data 1, the software revealed differences in the themes and their
frequencies in the form of a thematic summary. An example of
the thematic summary is presented in supplemental online data
2A. It demonstrated the statistical breakdown of themes with
100% frequency assigned to the most frequently occurring
theme, i.e., “medicinal” in the EMAdocuments. The frequency of
other themes’ appearance (i.e., “marketing,” “human,” and
“therapy”) or references (i.e., “Community,” “Directive,” and
“Agency”) was expressed as a percentage of the number using
this leading theme frequency as 100% (frequency assigned to
“medicinal”). Thewording behind each theme is presented in the
thematic summary shown in supplemental online data 2B. It in-
cludes explanation of the context of a theme (e.g., for “human,”
the context example is: “Substance: Any matter irrespective of
origin which may be: human, e.g., human blood and human
blood products”), as well as the number of occurrences (“hits”)
for each theme.
DISCUSSION
Differences and Similarities Among the Three
Regulatory Frameworks Analyzed
The conceptual map of documents provided three sources of
information about the content of documents: (a) main concepts
contained within the text and their relative importance, (2)
strengths of links between concepts (how often they co-occur),
and (c) similarities in the context in which they occur. This infor-
mation provided a powerful metric for statistically comparing
different documents. Arguably, this may be interpreted as a rep-
resentation of the document’s intent or purpose. Furthermore,
thismap canbeused to simply provide a bird’s eye viewof a large
amount of material such as compliance with multiple regulatory
frameworks’ requirements.
The document summary provides blocks of sentences con-
taining the most important concepts that appear on the map.
They are crucial segments of text demonstrating the relationship
between the defined concepts. Parts of the document summa-
ries are presented in supplemental online data 1, as an illustra-
tion of this type of analysis.
We found evidence of some shared aspects and terminology
within analyzed documents in this study. The 83.33% of most
frequently co-occurring concepts were shared between all GMP
documents in the analysis, irrespective of the frameworks from
which they originated. The GCP documents displayed consider-
ably higher concordance between different regulatory frame-
works than other analyzed documents. The GCP concept cloud
was the most consistent, with a fairly narrow range of concepts
surrounding “sponsor” and “trial” occupying the central posi-
tions. This clearly reflects the focus of all GCP documents revolv-
ing around one central concept regardless of the regulatory
framework from which they originated. The findings also sug-
gested that themost frequent concepts in the TGA, FDAandEMA
frameworks were “biological,” “product,” and “medicinal,” re-
spectively—all denoting a product as their focus point.
However, we also found a range of differences. For example, it
appeared that the FDA documents revolve around the themes
“HCT” (human cell and tissues) or “product,” with frequent refer-
ences to “CFR” and “section,” whereas the EMA documents are
mostly dominated by “medicinal,” “marketing,” and “public,” with
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numerous citations of “Commission” and “Directive.” The TGAdoc-
uments analysis has demonstrated only two main central themes:
“biological” (with numerous concepts) and “human.”
The lack of similarity found in both manual and software
analysis (i.e., different terminology, use of different phrases and
the difference in their co-occurrence frequency) supports part of
the hypothesis relating to differences between the frameworks.
It also demonstrates that formal terminology differences exist
widely throughout the regulatory frameworks, manifested in
their high-tier documents.
The complexity of the global regulatory environment re-
vealed in this study advocates application of a regulatory engi-
neering approach that would allow for a whole array of regula-
tory requirements to be met in more than one regulatory
framework. Similar to process engineering, the purpose of regu-
latory engineering would be to provide a solid setting for the
development of biologic drugs (which carries a significant
amount of uncertainty in its own intrinsic element). Develop-
ment of newbiologic drugs and biopharmaceuticals (i.e., cell and
tissue products) has led the existing regulatory agencies of the
developed world to propound new regulatory approaches—it
“has become one of the most research-intensive sectors with a
great potential for delivering innovative humanmedicines in the
future” [3]. Regulation of cell and tissue products is closely linked
not only to sensitive areas of public health policy and funding but
also to the development of novel disciplines such as regulatory
science [4, 5]. In view of the harmonization efforts between the
analyzed regulatory frameworks, this paper represents a contri-
bution to the recognition of similarities and differences between
them. It may also fill the literature gap and provide some foun-
dation for future comparative research of biologic drug regula-
tions on a global level.
Methodology and Software Used in the Study
Qualitative research often deals with in-depth analysis, fine dis-
tinction, and complexity; it is also based upon values of reason,
truth, and validity, though it can be context-contingent to some
degree [46, 47]. However, it is the researcherwho is the research
instrument in a qualitative study. This means that qualitative
research cannot entirely rely on standardized procedures to
deal with concepts such as bias and reproducibility [48].
Hence, researchers are required to reflect constantly and crit-
ically on the decisions they make during the course of a study,
to maintain transparency about the actual research design,
and to keep an audit trail regarding access to and collection
and analysis of the data [49]. For Leximancer software analy-
sis, concepts are defined as “collections of words that gener-
ally travel together throughout the text” [19]. The presence of
each word in a sentence provides an appropriate contribution
to the accumulated evidence for the presence of a concept
[22]. It means that a sentence (or group of sentences) is
tagged as a concept only if it contains enough accumulated
evidence—if the sum of the keyword loads is above the
threshold set in the software [22]. The software conducted
two forms of analysis. It measured the presence of defined
concepts in the text (conceptual analysis) and how they were
interrelated (relational or semantic analysis) (Figs. 1, 2). Apart
from allowing these differences to be explored visually, the
software explicitly stored the data relating to the frequency of
concept use (main concept frequencies represented in Table
2) and frequency of concept co-occurrence in a spreadsheet
file (represented in the form of 3D graphs in Fig. 3). Concepts
can either be explicit (i.e., particular words or phrases) or
implicit (i.e., implied, but not explicitly stated in a set of pre-
defined terms) [23]. Leximancer can automatically extract its
own dictionary of terms for each document set while using
this information. It is capable of assuming that the concept
classes that are present within the text are correct, unambig-
uously extracting a vocabulary of terms for each concept [19,
22]. There are commonly two applicable forms of reliability in
content analysis: stability and reproducibility. Stability refers
to the tendency of a coder (or a system) to consistently recode
the same information in the same way over time [23]. In the
automatic coding system (the software approach) many such
inconsistencies are avoided, leading to a high level of coding
stability [22]. Reproducibility refers to the consistency of clas-
sification provided by several coders within the same marking
scheme [23]. In the software, this issue is most pertinent to
the generation of the conceptual map. The process of map
generation is stochastic, leading to the possibility of different
final positions for the extracted concepts each time the map is
generated [19]. In order to maintain the maximal reproduc-
ibility of the software, which also affects its validity, we chose
not to change any of the software’s parameters and to use
only minimal manual intervention while performing the soft-
ware analysis. In some other qualitative content analysis tools
(e.g., NVivo; QSR International Pty. Ltd., Doncaster, VIC, Aus-
tralia, http://www.qsrinternational.com) it is required that
the analyst derive the list of codes and rules for attaching
them to the data [30]. This is not a prerequisite for the Lexi-
mancer application, hence eliminating the need for reliability
and validity checks. Leximancer, as a data-mining tool, uses
Bayesian logic to identify and visually present main concepts
within the text [45], and it is considered to be highly reliable,
stable, and valid in different applications [29, 33]. Relational
(semantic) analysis measures how identified concepts are re-
lated to each other within the documents. Two types of rela-
tional analysis were used in this study in order to measure the
relationships between the identified concepts. Proximity
analysis looks into co-occurrence of concepts found within
the text and cognitive mapping presents the information vi-
sually for comparison.
CONCLUSION
This paper has described the processes that were obtainedwhile
developing amethod of software documentary analysis for high-
tier regulatory documents. The results obtained in software
analysis are in concordancewith amanual analysis obtained [17],
and both sets of results are comparable. The research did not
provide any evidence about superiority either amanual or a soft-
ware-based approach, since they produced qualitatively differ-
ent sets of data (i.e., terminology and phrase frequency vs. con-
textual analysis). Theweaknesses of this type of study need to be
acknowledged. Data are studied out of context, and the selec-
tiveness of the data or representativeness of the sample can be
questioned. One of themain areas of criticism is the fact that the
whole study process is open to the subjective interpretation of
the researcher. Despite this criticism, this approach to documen-
tary analysis is particularly useful when the researcher is faced
with a vast number of complex documents with no common
format, scope, or terminology.
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Our findings indicate that some common groundwas iden-
tified between the documents originating from different reg-
ulatory frameworks. This was consistent with the manual ter-
minology search of the same documents [17]. There was no
evidence in the co-occurrence analysis to establish any shared
conceptual vocabulary between the regulatory frameworks.
As pointed out in the first part of the study [17], this research
draws attention to the importance of understanding the com-
plexity of a global regulatory environment attained by three re-
gional regulatory agencies. Although a vast array of differences
was identified in terms of terminology, concepts, and themes,
some shared aspects and common principles were also identi-
fied between the analyzed regulatory frameworks.
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